Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Viewpoints
Showing 2265 - 2272 of 12086 results

In Divided 3-2 Vote, Federal Trade Commission Authorizes Three Omnibus Compulsory Process Resolutions
August 30, 2022| Blog| Viewpoint

Summer 2022: Key Trends in Pharmacy Enforcement Actions
August 29, 2022| Blog| Viewpoint

Monthly TCPA Digest — August 2022
August 29, 2022| Article| Viewpoint

TCPA Regulatory Update — Commission Seeks Comment on Efficacy of STIR/SHAKEN; Commission Signs Robocall MOU
August 29, 2022| Article| Viewpoint

TCPA Litigation Update — Eleventh Circuit Hits the Brakes on Class Settlement
August 29, 2022| Article| Viewpoint

Energy & Sustainability Washington Update — September 2022
August 29, 2022| Blog| Viewpoint

Mintz's Role on Biolog-id SPAC included in 'Deal Watch'
August 29, 2022| News

Despite Federal Court Ruling, Efforts to Name AI an Inventor Likely to Continue
August 29, 2022| News
News & Press Releases
Mintz advised the creators of Morbid, one of the top-charting true crime podcasts, in a multi-year agreement to move to SiriusXM from Wondery. The deal gives SiriusXM exclusive advertising rights for the audio and video formats of the podcast.
Mintz Advises CVC DIF in Acquisition of SBA Communications’ Canadian Tower Infrastructure Platform
August 06, 2025
Mintz advised CVC DIF, the dedicated infrastructure investment strategy of global private markets manager CVC, in its agreement to acquire SBA Communications’ Canadian wireless tower business, one of Canada’s leading independent owners and operators of wireless communications towers. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions.
Mintz advised the underwriters in connection with a $69 million public offering by Larimar Therapeutics, Inc. of 21,562,500 shares of its common stock at a price to the public of $3.20 per share. The gross proceeds to Larimar from the offering were $69 million before deducting underwriting discounts and commissions and other offering expenses.
Events
Podcasts

Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|

Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|
